Latest Innovation News

Vitasora Health Limited has raised $11 million in a well-supported placement, positioning the company to achieve cash flow breakeven in the second half of FY2026. The capital injection underscores strong investor confidence following key contract expansions and operational milestones.

Horseshoe Metals secures $851,000 through a share placement and converts nearly $650,000 of debt into equity, aiming to accelerate development at its Horseshoe Lights Copper-Gold Project and fund exploration across Australia.

Battery Age Minerals has successfully raised $3 million to fund maiden drilling at its Bleiberg Germanium-Zinc Project in Austria and advance exploration at the El Aguila Gold-Silver Project in Argentina, attracting new investors and reinforcing its strategic position in critical minerals.

St George Mining has launched advanced geophysical surveys at its Araxá Niobium and Rare Earths Project in Brazil, aiming to pinpoint new high-grade mineralisation zones and support ongoing drilling efforts.

Neurizon Therapeutics has inked a pivotal global licensing deal with Elanco Animal Health, unlocking critical intellectual property and data to accelerate the development and commercialisation of its lead drug candidate NUZ-001 for neurodegenerative diseases including ALS.

Helia Group reveals ING Bank Australia will not renew its Lenders Mortgage Insurance contract beyond June 2026, prompting a strategic business review amid evolving market dynamics.

Talius Group has secured its first purchase order from Wesco Anixter and signed a global expansion agreement, while subscription numbers near 49,000 amid ongoing pilot programs and regulatory shifts.

EMVision Medical Devices has activated five of six pivotal trial sites for its emu™ bedside brain scanner, advancing towards FDA clearance while launching a parallel innovation study in Australia.

Peak Minerals reports a significant expansion of heavy mineral zones at its Minta Rutile Project in Cameroon, with consistent rutile mineralisation confirmed across a vast 1,500 square kilometres. The company advances toward a maiden Mineral Resource Estimate in 2026, supported by promising alluvial and residual assay results.

Echo IQ has initiated a pivotal clinical validation study with the Mayo Clinic Platform to test its EchoSolv HF software, marking the final step before its planned FDA submission in late 2025.

Mesoblast has secured FDA agreement on key requirements for its Biologics License Application for Revascor, targeting ischemic heart failure patients with reduced ejection fraction. The company aims for accelerated approval by year-end 2025.

Objective Corporation has agreed to acquire Isovist, a leading e-planning software provider for local governments in Australia and New Zealand, enhancing its Planning and Building sector capabilities.